Luis J, Martin J M, el Battari A, Fantini J, Giannellini F, Marvaldi J, Pichon J
Eur J Biochem. 1987 Sep 1;167(2):391-6. doi: 10.1111/j.1432-1033.1987.tb13350.x.
Incubation of monolayers of HT29-D4 cells (a clone of the human colonic adenocarcinoma cell line HT29) in the presence of 17.5 microM cycloheximide resulted in an increase in the number of vasoactive intestinal peptide (VIP) binding sites at the cell surface without any change in the affinity of receptor for its ligand. The increase in 125I-VIP-binding capacity was dose-dependent between 0.35 microM and 17.5 microM cycloheximide and was correlated with the inhibition of protein biosynthesis. At higher concentrations of drug (17.5-100 microM) a plateau corresponding to a twofold increase in VIP-binding capacity was reached independently of the extent of protein synthesis inhibition. We found that VIP receptors of HT29-D4 cells with such an enhanced binding capacity behaved like those of control cells with respect to receptor internalization and recycling (i.e. the cycle of occupied receptors was insensitive to cycloheximide). After inactivation of 90% of cell-surface VIP receptors by alpha-chymotrypsin, we observed a biphasic kinetic of reappearance of VIP-binding sites. 40% of VIP-binding sites reappeared very quickly (less than 5 min) and 100% within 17 h. The fast recovery of VIP receptors was probably due to the deployment of new binding sites from an intracellular pool. The rate and extent of recovery of these receptors were similar in control cells and in cycloheximide-treated cells. However, the slow recovery was inhibited in cycloheximide-treated cells probably because a pool of immature receptors was depleted by the drug before the alpha-chymotrypsin treatment. Our data are consistent with the existence of two different intracellular pathways of occupied and unoccupied VIP receptors.
在17.5微摩尔环孢霉素存在的情况下培养HT29 - D4细胞单层(人结肠腺癌细胞系HT29的一个克隆),导致细胞表面血管活性肠肽(VIP)结合位点数量增加,而受体对其配体的亲和力没有任何变化。在0.35微摩尔至17.5微摩尔环孢霉素之间,125I - VIP结合能力的增加呈剂量依赖性,并且与蛋白质生物合成的抑制相关。在更高浓度的药物(17.5 - 100微摩尔)下,达到了与VIP结合能力增加两倍相对应的平台期,与蛋白质合成抑制的程度无关。我们发现,具有这种增强结合能力的HT29 - D4细胞的VIP受体在受体内化和再循环方面(即被占据受体的循环对环孢霉素不敏感)表现得与对照细胞的受体相似。在用α - 胰凝乳蛋白酶使90%的细胞表面VIP受体失活后,我们观察到VIP结合位点重新出现的双相动力学。40%的VIP结合位点很快重新出现(不到5分钟),17小时内100%重新出现。VIP受体的快速恢复可能是由于从细胞内池部署了新的结合位点。这些受体的恢复速率和程度在对照细胞和环孢霉素处理的细胞中相似。然而,在环孢霉素处理的细胞中,缓慢恢复受到抑制,可能是因为在α - 胰凝乳蛋白酶处理之前,药物耗尽了一组未成熟的受体。我们的数据与存在两种不同的被占据和未被占据的VIP受体细胞内途径一致。